ZD9331: Discovery to clinical development

Anti-Cancer Drugs

Volumn 16, Issue 1, 2005, Pages 1-9

  Benepal, T S ^a,b   Judson, I ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Clinical development; Discovery; Folylpolyglutamate syntnetase; Raltitrexed; Thymidylate synthase; ZD9331

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLATE RECEPTOR; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; GEMCITABINE; PACLITAXEL; PLATINUM; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE; TOPOTECAN;

ABDOMINAL PAIN; ANEMIA; BONE MARROW TOXICITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG RETENTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; LYMPHOCYTOPENIA; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG EVALUATION; FEMALE; HUMANS; NEOPLASMS; OVARIAN NEOPLASMS; QUINAZOLINES; THYMIDYLATE SYNTHASE;

EID: 12544249137     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200501000-00001     Document Type: Review

References (48)

1. Jones TR. Calvert AH. Jackman AL, Brown SJ, Jones M, Harrap KR. A potent antitumor quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Eur J Cancer 1981; 17:11-19.
2. 10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem Pharmacol 1991; 42:1885-1895.
3. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, et al. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 1997; 3:911-921.
4. 4-hydroxyquinazoiines as inhibitors of thymidylate synthetase. Mol Pharmacol 1970; 6:573-575.
5. Calvert AH, Jones TR, Dady PJ, Grzelakowska-Sztabert B, Paine RM, Taylor GA. et al. Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance. Eur J Cancer 1980; 16:713-722.
6. Jones TR. 5-Substituted quinazoline antifolates. Eur J Cancer 1980; 16:707-711.
7. 10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro. Biochem Pharmacol 1988; 37: 4047-4054.
8. 10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol 1986; 4:1245-1252.
9. Clarke SJ, Jackman AL, Judson IR. The history of the development and clinical use of CB3717 and ICI D1694. In: Rustum YM (editor): Novel Approaches to Selective Treatments of Human Solid Tumors. New York: Plenum Press; 1993, pp. 277-284.
10. Jones TR, Thornton TJ, Flinn A, Jackman AL, Newell DR, Calvert AH. Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency. J Med Chem 1989; 32:847-852.
11. 2 position. J Med Chem 1990; 33: 3060-3067.
12. Taylor GA, Jackman AL, Balmanno K, Hughes LR, Calvert AH. Estimation of the in vitro and in vivo inhibitory effects of antifolates upon thymidylate synthase (TS) in whole cells. Adv Exp Med Biol 1989; 253B:383-388.
13. Takemura Y, Kobayashi H, Gibson W, Kimbell R, Miyachi H, Jackman AL. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1 694 in cultured human leukemia cells. Int J Cancer 1996; 66:29-36.
14. Jackman AL, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne GW, et al. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1 694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 1995; 71:914-924.
15. Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, et al. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 1996; 14:1495-1503.
16. Smith I, Jones A, Spielmann M, Namer M, Green MD, Bonneterre J, et al. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer 1996; 74:479-481.
17. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
18. Theti DS, Jackman AL. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res 2004; 10:1080-1089.
19. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997; 74:193-198.
20. Aherne GW, Hardcastle A, Ward E, Dobinson D, Crompton T, Valenti M, et al. Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase in a murine model following two curative administration schedules. Clin Cancer Res 2001; 7:2923-7930.
21. Boyle FT. ZD9331 Preclinical and clinical studies. In: Jackman AL (editor): Antifolate Drugs in Cancer Therapy. Totowa, NJ: Humana Press: 1999. pp. 243-260.
22. Goh BC, Ratain MJ, Bertucci D, Smith R, Mani S, Vogelzang NJ, et al. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol 2001; 19: 1476-1484.
23. Rees C, Beale P, Trigo JM, Mitchell F, Jackman A, Smith R, et al. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies. Clin Cancer Res 2003; 9:2049-2055.
24. Diab S, Britten C, Eckhardt G, Hammond L, Elledge R, Siu L, et al. Phase and pharmacokinetic (PK) study of the non-polyglutamated thymidylate synthase (TS) inhibitor ZD9331 given as a 30 min infusion every 3 weeks. Proc Am Soc Clin Oncol 1998; abstr 869.
25. Plummer R, Rees C, Hughes A, Beale P, Highley M, Trigo J, et al. A Phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor. Clin Cancer Res 2003; 9:1313-1322
26. Koizumi W, Aiba K, Sasaki T, Sato A, Horikoshi N. Phase I dose-escalation trial of ZD9331 in Japanese patients with refractory, solid malignancies. Anticancer Drugs 2003; 14(suppl 1):S1-S5.
27. de Jonge MJ, Punt CJ, Sparreboom A, Planting AS, Peters ME, van De Schraaf J, et al. Phase I and pharmacologic study of oral ZD9331, a novel nonpoiyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. J Clin Oncol 2002; 20:1923-1931.
28. Sawyer MB, Ratain MJ, Bertucci D, Smith RP Schilsky RL, Vogelzang NJ. et al. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol 2003; 21:1859-1865.
29. de Jonge MJ, Glimelius B. Verweij J, Van Groeningen C, Bonneterre J, de Vries EG, et al. Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. Anticancer Drugs 2002; 13:645-653.
30. 14C]-ZD9331 Infused over 30 minutes in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001; abstr 350.
31. Petruzelka L. Phase II multicentre trial of ZD9331 monotherapy as first-line treatment for gastric cancer. Anticancer Drugs 2003; 14(suppl 1):S7-S12.
32. Kelleher M, Tebbutt NC, Cunningham D, Andreyev J, Allen M, Hill M, et al. Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies. Clin Oncol (R Coll Radiol) 2003; 15:92-97.
33. Windschitl HE, O'Connell MJ, Wieand HS, Krook JE, Rubin J, Moertel CG, et al. A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. Cancer 1990; 66:853-886.
34. Hainsworth J, Vergote I, Janssens J. A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumors. Anticancer Drugs 2003; 14(suppl 1):S13-S19.
35. Woll PJ, Basser R, Le Chevalier T, Drings P, Perez Manga G, Adenis A, et al. Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer. Br J Cancer 1997; 76:264-265.
36. Schulz J, Douglass E. ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicentre trial. Ann Oncol 2000; 11(suppl 4): 62 (abstr 270PD).
37. Louvet C, Thierry A, Gamelin E, Line Garcia M, Lenaers G, Kalla S. A phase I/II intra-patient dose escalating trial of ZD9331 in combination with irinotecan (CPT11) as second-line treatment for patients (pis) with metastatic colorectal cancer. Ann Oncol 2002; 13(suppl 5):76 (abstr 276P).
38. Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, et al. Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies. Cancer Chemother Pharmacol 2004; 53:357-360.
39. Wood S, Schwartz G, Garrison MA, McCreery H, Tolcher A, Patnaik A, et al. A phase I, dose-escalating trial of ZD9331 in combination with docetaxel in patients with refractory solid malignancies. Proc Am Soc Clin Oncol 2002; abstr 1843.
40. Smith D, Gallagher N. A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer. Eut J Cancer 2003; 39:1377-1383.
41. Benson A, Poplin 3rd E. Vergote I. ZD9331 in combination with topotecan: phase I and II experience. Anticancer Drugs 2003; 14(suppl 1):S21-S27.
42. Gore ME, Earl HM, Cassidy J, Tattersall M, Mansi J, Seymour L, et al. A phase II study of Tomudex in relapsed epithelial ovarian cancer. Ann Oncol 1995; 6:724-725.
43. Look KY, Muss HB1 Blessing JA, Morris M. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 1995; 18:19-22.
44. Jackman AL, Meln CJ, Kimbell R, Brunton L, Aherne GW, Theti DSm ea at/. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumors. Biochim Biophys Acta 2002 1587:215-223.
45. Kelland LR, Kimbell R, Hardcastle A, Aherne GW, Jackman AL. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumor cell lines. Eur J Cancer 1995; 31A:981-986.
46. Jackman AL, Gibson W, Brown M, Kimbell R, Boyle FT. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv Exp Med Biol 1993; 339:265-276.
47. Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, et al. A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol 2003; 91:318-325.
48. Benepal TS, Pyle P, Bate S, Hardcastle A, Wynne Aherne G, Mitchell F, et al. A pharmacokinetic (PK) phase I (PI) study of ZD9331 and carboplatin in relapsed ovarian cancer (ROC) with a pharmacodynamic (PD) endpoint. Eur J Cancer 2002; 38:P24 (abstr 64).